Tag: SMA
-

Scholar Rock’s Isembyld Wins FDA Approval for Spinal Muscular Atrophy
The FDA approved Scholar Rock’s Isembyld for patients aged two years and older receiving SMN2-targeted therapy, adding the first muscle-directed treatment to established SMA care.